Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
1984-7-13
|
pubmed:abstractText |
A solid-phase, noncompetitive radioimmunoassay has been developed for aldolase B in human serum and tissues. Aldolase B was purified from human liver, and specific antisera to purified aldolase B were obtained from chickens. Specific antihuman aldolase B IgG was purified by affinity chromatography. Disposable polypropylene plates were coated with affinity purified specific IgG antibody and used for radioimmunoassay with 125I-specific IgG antibody to aldolase B. The nonspecific binding was minimized by saturating the binding sites of the plates with 2% ovalbumin in 0.1% Tween 20. This radioimmunoassay is specific for the aldolase B subunit, with no cross-reactivity with human aldolase A or aldolase C subunits. Aldolase B is predominantly found in normal liver. Relatively high aldolase B levels are also observed in kidney. Serum levels of aldolase B in 21 normal subjects ranged from 21 to 39 ng per ml, with a mean of 28.7 +/- 8.6 (2 S.D.) ng per ml. Forty of 42 (95%) patients with acute and chronic hepatitis without cirrhosis had serum aldolase B levels greater than 40 ng per ml. Serum aldolase B levels correlated well with total serum aldolase enzyme activities (r = 0.967) and SGPT (r = 0.951) in patients with liver diseases. In cancer patients, serum aldolase B was slightly elevated in 15 of 26 (58%) patients with cancer metastatic to the liver or primary liver cell carcinoma, whereas no elevation of serum aldolase B was observed in 16 cancer patients without liver metastasis. Measurements of aldolase B serum levels by radioimmunoassay appear to be a useful measure of liver cell necrosis from benign or malignant liver diseases.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:issn |
0270-9139
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
4
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
531-5
|
pubmed:dateRevised |
2007-11-15
|
pubmed:meshHeading |
pubmed-meshheading:6724519-Alanine Transaminase,
pubmed-meshheading:6724519-Animals,
pubmed-meshheading:6724519-Chickens,
pubmed-meshheading:6724519-Clinical Enzyme Tests,
pubmed-meshheading:6724519-Female,
pubmed-meshheading:6724519-Fructose-Bisphosphate Aldolase,
pubmed-meshheading:6724519-Hepatitis,
pubmed-meshheading:6724519-Humans,
pubmed-meshheading:6724519-Isoenzymes,
pubmed-meshheading:6724519-Liver,
pubmed-meshheading:6724519-Liver Cirrhosis,
pubmed-meshheading:6724519-Liver Diseases,
pubmed-meshheading:6724519-Liver Neoplasms,
pubmed-meshheading:6724519-Radioimmunoassay,
pubmed-meshheading:6724519-Time Factors,
pubmed-meshheading:6724519-Tissue Distribution
|
pubmed:articleTitle |
Human aldolase B serum levels: a marker of liver injury.
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.
|